Novartis | NOVN - Selling And Administration Expenses

Stock Price
116.63
Daily Change
-0.61 -0.52%
Monthly
7.49%
Yearly
22.01%
Q1 Forecast
111.83

Novartis reported $3.31B in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Alcon AG USD 865M 5M Sep/2025
Amgen USD 1.7B 9M Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
Autolus Therapeutics Ltd USD 27.96M 1.58M Jun/2025
Bayer EUR 3.4B 140M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Fresenius EUR 676M 64M Sep/2025
Fresenius Medical Care EUR 705.44M 86.56M Sep/2025
Galapagos EUR 34.55M 3.88M Sep/2025
Genmab DKK 144M 18M Jun/2025
Gilead Sciences USD 1.35B 6M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
GRIFOLS EUR 284.99M 2.24M Sep/2025
Hikma Pharmaceutical USD 139M 149M Jun/2025
J&J USD 6.75B 831M Dec/2025
Merck EUR 1.46B 16M Sep/2025
Merck USD 2.63B 0 Sep/2025
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Novo Nordisk DKK 18.85B 2.74B Jun/2025
Orion EUR 84.6M 12.1M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Philips EUR 1.18B 61M Sep/2025
Recordati EUR 171.38M 15.6M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.29B 221M Dec/2024